Topical cold sore treatments and valaciclovir trim recovery by one day

Topical Antivirals Trim One Day Off Cold Sore Recovery

The evaluation looked at 87 studies involving 22,631 participants. It found that while antiviral topical creams offer modest relief without increasing adverse events, oral medications show varied effectiveness.

Valaciclovir tablets also accelerate healing by about one day. Conversely, oral aciclovir results in little to no difference in recovery time compared to a placebo.

Weighing Topical Creams Against Oral Medications

Cold sores, also known as fever blisters, are painful and contagious lesions around the mouth triggered by the herpes simplex virus. Standard medical therapies aim to stop viral multiplication using topical creams or oral pills.

The evidence review examined multiple therapeutic approaches tested across Europe, North America, Australia, and Asia. It focused primarily on adults with healthy immune systems.

Out of 58 total treatments evaluated in the literature, topical aciclovir cream demonstrated a reduction in healing time by approximately one day across seven studies comprising 3,475 people. Similarly, data from one study involving 528 participants showed that penciclovir cream speeds up healing by about one day.

When comparing oral medications against a placebo, researchers found contrasting outcomes. Two studies involving 1,218 participants indicated that valaciclovir tablets shorten healing duration by about one day. A single study of 145 patients taking aciclovir tablets showed little to no effect on overall recovery time.

Unwanted side effects remained uncommon across all evaluated interventions. Studies assessing aciclovir and penciclovir topical treatments reported no increased risk of serious, mild, or moderate adverse events. Similarly, patients taking valaciclovir experienced mild or moderate side effects at rates comparable to those using a placebo.

Direct Drug Comparisons and Missing Outcome Data

Direct comparisons between different active interventions yielded limited direct data. One study involving 225 participants comparing penciclovir cream directly against aciclovir cream noted similar healing effects and comparable risks of mild or moderate adverse events.

Investigators found no existing studies directly contrasting topical aciclovir cream with oral aciclovir tablets. While the review sought to analyze symptom improvement, pain severity, and overall lesion severity, no studies on the most common interventions provided data that could be analyzed for those specific outcomes.

Methodological Gaps and Industry Funding

Authors of the evidence review expressed moderate or low confidence in much of the data, primarily because individual study sample sizes were small.

Additional therapies like photodynamic therapy, laser treatments, zinc patches, and topical propolis lack extensive supportive research. Because the vast majority of trial participants were adults, researchers have limited certainty regarding how these antiviral treatments function in children.

Geographic representation also showed gaps, with very few investigations conducted in East Asia or low-resource settings. Funding for 43 of the analyzed studies came from the pharmaceutical industry. Meanwhile, 25 trials relied on non-profit organization backing, one reported no funding, and 18 did not disclose their funding sources.